Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
248 studies found for:    sirolimus cancer | Open Studies
Show Display Options
Rank Status Study
21 Recruiting Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer
Condition: Endometrial Cancer
Interventions: Device: Levonorgestrel Intrauterine Device (LIUD);   Drug: Everolimus;   Behavioral: Questionnaire
22 Recruiting Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
Condition: Refractory Hurthle Cell Thyroid Cancer
Interventions: Drug: sorafenib;   Drug: everolimus
23 Recruiting Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane
Conditions: Hormone Receptor Positive Malignant Neoplasm of Breast;   Metastatic Breast Cancer
Intervention: Drug: Everolimus plus Exemestane
24 Recruiting Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Carboplatin;   Drug: Everolimus
25 Recruiting A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer
Condition: Advanced Solid Tumors, Non-small Cell Lung Cancer
Intervention: Drug: AMG 479, Everolimus, Panitumumab
26 Recruiting Aging Mammary Stem Cells and Breast Cancer Prevention
Condition: Cancer of Breast
Intervention: Drug: Rapamycin
27 Recruiting A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer
Condition: Bladder Cancer
Intervention: Drug: Sirolimus
28 Recruiting A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
Conditions: Solid Tumors;   Lung Cancer
Interventions: Drug: BKM120;   Drug: Everolimus
29 Recruiting Palbociclib With Everolimus + Exemestane In BC
Conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   Hormone Receptor (HR)-Positive Breast Cancer
Interventions: Drug: Palbociclib;   Drug: Everolimus;   Drug: Exemestane
30 Recruiting PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI
Condition: Metastatic Renal Cancer
Intervention: Drug: Prednisone + Everolimus
31 Recruiting Women's Triple-Negative First-Line Study: Liposomal Doxorubicin, Bevacizumab and Everolimus (DAE) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy
Condition: Breast Cancer
Interventions: Drug: Everolimus;   Drug: Liposomal Doxorubicin;   Drug: Bevacizumab
32 Recruiting Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Condition: Breast Cancer
Interventions: Drug: LEE011;   Drug: Exemestane;   Drug: Everolimus
33 Recruiting A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
Condition: Desmoid Tumor
Intervention: Drug: Sirolimus
34 Recruiting Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors
Condition: Cancer
Interventions: Drug: Sirolimus;   Drug: Celecoxib;   Drug: Etoposide;   Drug: Cyclophosphamide
35 Recruiting Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor-negative;   Stage IV Breast Cancer;   Triple-negative Breast Carcinoma
Interventions: Drug: everolimus;   Drug: eribulin mesylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
36 Recruiting PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
Conditions: Sarcoma;   Malignant Peripheral Nerve Sheath Tumors
Interventions: Drug: PLX3397;   Drug: Sirolimus
37 Recruiting Study of GnRH Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Everolimus(afinitor);   Drug: Letrozole;   Drug: Leuprolide
38 Recruiting Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers
Condition: Triple Negative Breast Cancer
Interventions: Drug: Everolimus;   Drug: Eribulin
39 Recruiting Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy
Conditions: Primary Non-metastatic Breast Cancer;   Who Remain Disease-free
Interventions: Drug: Everolimus;   Drug: Placebo
40 Recruiting Prediction of Everolimus-induced Interstitial Lung Disease
Condition: Breast Neoplasms
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.